同步放化疗联合重组人血管内皮抑制素治疗中晚期宫颈癌52例疗效分析

目的观察同步放化疗联合重组人血管内皮抑制素(恩度)对中晚期宫颈癌的近期疗效。方法将52例中晚期(Ⅱb～Ⅳa期)宫颈癌患者随机分为2组:放化疗组(CRT组)26例,恩度联合放化疗组(CRT+E组)26例。CRT组:采用23-EX Vrian直线加速器15MvX线外放疗+Ir192高计量率后装放疗。每周1次顺铂20 mg/m2静脉滴注,第1天,共4周。CRT+E组:放化疗方法 CRT组相同,在放疗开始每天1次恩度7.5 mg/m2静脉滴注,共4周。结果近期临床疗效:CRT+E组CR 19例(73.1%),PR 6例(23.1%),NC 1例(3.8%),有效率96.2%;CRT组CR 9例(34.6%),PR 11例(42.3%),NC 6例(23.1),有效率76.9%,CRT+E组的有效率高于CRT组,差异有统计学意义(P<0.05)。CRT+E组1年生存率100%(26/26),CRT组1年生存率84.6%(22/26),差异有统计学意义(P<0.05)。结论同步放化疗联合重组人血管内皮抑制素(恩度)可提高中晚期宫颈癌的近期疗效,不良反应没有增加。

The Early Efficacy of the Endostar Combined with Chemoradiotherapy to the Advanced Cervical Cancer

Objective To investigate the early outcome of the Endostar combined with chemoradiotherapy to the advanced cervical cancer.Methods Fifty-two cases with cervical cancer（FIGO Ⅱb to Ⅳa）were divided randomly into two groups,Chemoradiotherapy group（CRT group） and Endostar combined with chemoradiotherapy group（RT＋E group）.There was no difference of chemoradiotherapy between the two groups,The CRT＋E cases who accepted Endostar during the radiation,according to 7.5 mg/m^2·d,cisplatin once weekly injection of vain,according to 20 mg/m^2,These regimen were given for 4 weeks.Results In CRT＋E group：CR cases,PR 6 cases,NC 1 case,in CRT group CR 9 cases,PR 11 cases,NC 6 cases,The early outcome：The complete remission rate was 73.1%,partial remission rate was 23.1% and the total response rate was 96.2% in CRT＋E group.The complete remission rate was 34.6%,partial remission rate was 42.3% and the total response rate was 76.9% in CRT group.The total response rate of CRT＋E group was higher than that of the CRT group.There was significant difference between the two groups.One year survive rate was 100% and 84.6% in CRT＋E group and CRT group respectively.There was significant difference between the two groups.Conclusion the Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer,and the adverse effects was not raised.